Ipilimumab
ایپیلیموماب
🎗️ Antineoplastic And Immunomodulating AgentsCTLA-4 blocking antibody
Market / country: 🇺🇸 USA
Yervoy (US)
🧮 Dose calculator
Melanoma · Regimen source: FDA Yervoy · 2.2
- • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Yervoy · 2.2
- • Combinations with nivolumab and other indications (renal, colorectal, liver, lung, mesothelioma): different dose and interval per section 2. FDA Yervoy · 2
Enter age and weight.
🛡️ Safety & information
Warnings
- • Severe and fatal immune-mediated reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin); infusion reactions; complications of allogeneic HSCT; embryo-fetal toxicity. FDA Yervoy · 5
Formulations
- 5 mg/mL (50 mg/10 mL, 200 mg/40 mL) — injection 🇺🇸 USA FDA Yervoy · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Yervoy · 8.1
“Risk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1) ] , YERVOY can cause fetal harm when administered to a pregnant woman.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Yervoy · 8.2
“Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with YERVOY and for 3 months following the last dose.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Yervoy · 8.4
“The safety and effectiveness of YERVOY have been established in pediatric patients aged 12 years and older for the following indications: as a single agent and in combination with nivolumab for unresectable or metastatic melanoma, in combination with nivolumab for the treatment of MSI-H or dMMR unresectable and …”
- 👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Yervoy · 8.5
“No overall differences in safety or effectiveness were observed between these patients and younger patients.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Yervoy · 8.3
“Contraception YERVOY can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .”
🔗 Reference links
- FDA (approval record)BLA125377
- DailyMed (FDA label)FDA Yervoy
- MedlinePlus (NIH)Ipilimumab Injection
- WHO ATC/DDDL01FX04
- Darooyab (Iran)Ipilimumab
🇮🇷 Registered in Iran Darooyab · G-4764/Ipilimumab
Dosage forms with Iranian generic codes, per Darooyab.
- 21572 · IPILIMUMAB 200MG/40ML VIAL · ویال ایپیلیمومب ۲۰۰ میلیگرم / ۴۰ میلیلیتر
- 23984 · IPILIMUMAB INJECTION, SOLUTION, CONCENTRATE PARENTERAL 5 mg/1mL 10 mL · کنسانتره محلول تزریقی ایپیلیمومب ۵ میلیگرم / ۱ میلیلیتر ۱۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Yervoy · 3FDA Yervoy · 2.2FDA Yervoy · 2FDA Yervoy · 5FDA Yervoy · SPL approval / marketing categoryFDA Yervoy · 8.1FDA Yervoy · 8.2FDA Yervoy · 8.4FDA Yervoy · 8.5FDA Yervoy · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4764/Ipilimumab
- Clinical review⚠ Unverified